ADVERSE DRUG REACTION
Sulfasalazine-induced immune thrombocytopenia
1 Rheumatology Unit, Department of Clinical Medicine and Immunological Sciences, University of Siena, Italy
2 Department of Clinical and Experimental Medicine, University of Verona, Italy
Correspondence to:
Correspondence to:
Dr Ilaria Tinazzi
Department of Clinical and Experimental Medicine, University of Verona, Pz.le Scuro,10 37134; Verona, Italy; ilariatinazzi{at}yahoo.it
Sulfasalazine is a well established disease-modifying anti-rheumatic drug commonly used in the treatment of rheumatic disorders and inflammatory bowel disease. Sulfasalazine was generally well tolerated in clinical trials, the most frequently reported adverse effects being adverse gastrointestinal effects, headache, dizziness and rash; myelosuppression can also occur. We are now reporting the first case of autoimmune thrombocytosis following sulfasalazine treatment.
Abbreviations: NSAIDs, non-steroidal, anti-inflammatory drugs; SLE, systemic lupus erythematosus; TNF
, tumour necrosis factor 
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
